Preliminary data from a phase 4 post-marketing safety trial of the arthritis drug tofacitinib have turned up worrying results for the Janus kinase (JAK) inhibitor, indicating an elevated risk of causing heart problems and cancer in some patients. Read more in The Lancet Rheumatology.